No Data
Stocks that moved the previous day part 2: Metaplanet, Yamagata University, Ikuyo ETC.
Stock Name <Code> 20-day closing price ⇒ Compared to the previous day. BEIKARENT <6532> 5758 -134; a calm after the price increase following the Earnings Reports. NEXELAPHARMA <4565> 979 -19; profit-taking by short-term funds after last weekend's rapid surge. KIOXIA HD <285A> 1708 -80; caution against some tabloid reports. CELES <3696> 3035 -60; seen as a supply-demand factor, but among Cryptos-related stocks, the resistance at higher levels is noticeable. NINTENDO CO LTD <7974> 8901 -280; MOL.
The Tokyo Stock Exchange Growth Market Index rebounded, although it slightly lost momentum towards the end, marking a solid day.
The TSE Growth Market Index is 810.88, up by 6.87, with a Volume of 0.1 billion shares (53.93 million shares) and a trading value of 96.5 billion yen. The TSE Growth Market 250 Index is 631.26, up by 5.41, with a Volume of 99.52 million shares and a trading value of 81.3 billion yen. In today's growth market, both the TSE Growth Market Index and the TSE Growth Market 250 Index rebounded. The number of rising stocks is 380, the number of falling stocks is 182, and the unchanged stocks are 40. On the 17th in the USA market, the Dow Inc increased by 334.70 dollars, reaching 43,487.83 dollars.
Stocks that moved or were traded in the first half of the session.
*System Research <3771> 1545 +204, favorably received the announcement of this period's dividend increase. *TAKARA & COMPANY <7921> 3240 +342, large shareholding of Miller Capital has become apparent. *Daiichi Sankyo <4568> 4450 +369, positively received the FDA approval of "Datroway." *UNITIKA <3103> 147 +11, rebound is anticipated considering the firmness of the lower price. *Fuji HD <4676> 1826 +135.5, speculation about acquisitions is surfacing but telecommunications.
Emerging Markets stock digest: Enechange continues to rise, Ekonavista rebounds significantly.
<4593> Helios 235 +4 is in consolidation. It has announced that it has signed a basic agreement for a business alliance with its subsidiary Cell Resources for the production of cell culture supernatants. Helios is planning to establish a manufacturing base for the cell culture supernatants provided under the supply contract with AND medical, and regarding the launch and subsequent operations, it will collaborate with Cell Resources, which is engaged in the supply of cell raw materials and the manufacturing of cell products, according to the agreement.
DWTI---consolidating, announced an upward revision of financial estimates.
Consolidation. After the close of trading on the 16th, an upward revision of the full-year financial estimates for the fiscal year ending December 2024 was announced, leading to initial buying, but resistance at higher prices. Revenue was revised upward from 0.4 billion yen to 0.471 billion yen (a 17.8% increase), and ordinary profit and loss was revised from a deficit of 1.51 billion yen to a deficit of 1.228 billion yen (the previous period was a deficit of 0.796 billion yen). Regarding revenue, the increase is attributed to strong royalty income from the Ophthalmology surgical assist product "DW-1002" in European and USA markets, and in terms of profit, the usage of research and development expenses is.
Accel M, Helios and others [Emerging Markets press release]
＜3624＞ The exercise number of the 29th subscription rights of Axcell M (with exercise price revision clause) to be issued from the 7th is 1.06 million 4600 shares. ＜4576＞ DWTI upward revision, current period operating loss forecast is △1.209 billion yen, down from △1.5 billion yen. ＜4579＞ Rakuja Pharmaceutical's TRPV4 antagonist (pyrimidine-4(3H)-one derivative) patent assessment in China. ＜4593＞ Cell Resources, which is engaged in the supply of Helios cell materials, is moving towards providing business related to the production of cell culture supernatant.